Alpha 2.0
Login Register
» Journals » Neuropsychopharmacol Rep

Neuropsychopharmacology Reports

Neuropsychopharmacology Reports is a scientific journal, published since 2018 in English. The journal's country of origin is United States and its primary focus areas are neurology and pharmacology.
Details
Abbr. Neuropsychopharmacol Rep
Start 2018
End Continuing
Frequency Six issues a year
e-ISSN 2574-173X
Country United States
Language English
Specialties Neurology
Pharmacology
Metrics
h-index / Ranks: 11956 22
SJR / Ranks: 6783 660
CiteScore / Ranks: 7822 3.40
Recent Articles
1.
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis
Urata M, Sakurai H, Ueno F, Maruki T, Tada T, Uchida T, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70008. PMID: 40014460
Background: Mild depression lacks a consistent definition across diagnostic criteria and rating scales, posing challenges to standardizing treatment strategies. International guidelines predominantly recommend psychotherapy as the first-line treatment for mild...
2.
Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders
Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70010. PMID: 40011069
One of the challenges in diagnosing psychiatric disorders is that the results of biological and neuroscience research are not reflected in the diagnostic criteria. Thus, data-driven analyses incorporating biological and...
3.
The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia-Pacific Region: A Cross-Sectional Real-World Study
Herr K, Berk M, Huang W, Kato T, Lee J, Ng C, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70007. PMID: 40011065
Aim: Anhedonia is a key symptom of major depressive disorder (MDD), however, its burden in patients with MDD is not well understood. We aimed to assess the impact of anhedonia...
4.
Epigenetic Clock Analysis for National Institutes of Health Stroke Scale in Patients With Ischemic Stroke
Jiang W, Shirai T, Otsuka I, Okazaki S, Tanifuji T, Horai T, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70009. PMID: 39985312
Aim: Strokes are the second most common cause of mortality and disability worldwide. Ischemic strokes account for the main part of strokes. Recently, the epigenetic changes that occur during biological...
5.
Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database
Inada K, Muraoka H, Matsumoto Y, Fukui D, Watanabe T, Masuda Y, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70003. PMID: 39981596
Background: Laxative use has recently been indicated as a risk factor for hospitalization in patients with schizophrenia. Oral antipsychotic therapy for patients with schizophrenia treated with laxatives may be problematic...
6.
A Report of Three Cases With Dissociative Disorder: Some Positive Response to Methylphenidate Extended Release Used for Their Concurrent Attention Deficit Hyperactivity Disorder
Okano K
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70004. PMID: 39981589
Although no psychotropic medication is specifically effective for dissociative symptoms, certain abusive substances can markedly alter these symptoms. Regarding psychotropic medications, a positive response was observed in certain patients with...
7.
A Longitudinal Study of the Association of Blood Unsaturated Fatty Acids With Posttraumatic Stress Disorder (PTSD)
Inoue T, Ogawa S, Narita Z, Sekiguchi M, Asari Y, Kataoka Y, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e12522. PMID: 39963001
Aim: This study aimed to investigate the association between blood fatty acid fractions and posttraumatic stress disorder (PTSD) judgment in individuals who have experienced physical trauma. Methods: Patients admitted to...
8.
Usefulness of the WAIS-IV Short Form for Measuring Cognitive Function in Patients With Schizophrenia
Ito S, Sumiyoshi C, Matsumoto J, Miura K, Yasuda Y, Hasegawa N, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):1-6. PMID: 39936235
Schizophrenia causes cognitive dysfunction. The assessment of cognitive function is important in the treatment of schizophrenia. The Wechsler Adult Intelligence Scale (WAIS) is used to assess cognitive function in patients...
9.
Gene Expression Profiling in the Cortex of Fabp4 Knockout Mice
Kirikae H, He X, Ohnishi T, Miyazaki H, Yoshikawa T, Owada Y, et al.
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70006. PMID: 39921359
Aims: Fatty acid binding protein 4, adipocyte (Fabp4), is well known for its role in peripheral lipid metabolism, but its potential role in brain function remains largely unexplored. This study...
10.
Effectiveness of Attentional Bias Modification Combined With Cognitive Behavioral Therapy in Reducing Relapse Risk and Cravings in Male Patients With Alcohol Use Disorder: A Quasi-Randomized Controlled Trial
Amano Y, Koizumi K, Takizawa H, Tasaka S, Hamaguchi T
Neuropsychopharmacol Rep . 2025 Feb; 45(1):e70002. PMID: 39907051
Background: Alcohol use disorder (AUD) is characterized by severe dependence on alcohol, poor impulse control, and heightened attention to alcohol-related cues. Attention bias modification (ABM) retrains individuals to distract attention...